EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSLACG00000011471
Gene Symbol: GRIN3A
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSLACG00000015454
Gene Symbol: GRIN3B
4 Cross references
286 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSLACG00000009256
Gene Symbol: GRIK1
3 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSLACG00000001413
Gene Symbol: GRIK2
4 Cross references
334 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSLACG00000018024
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSLACG00000005660
Gene Symbol: GRIK4
4 Cross references
261 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSLACG00000011972
Gene Symbol: GRIK5
4 Cross references
303 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSLACG00000017120
Gene Symbol: GRM2
4 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSLACG00000010216
Gene Symbol: GRM3
4 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSLACG00000003503
Gene Symbol: GRM4
4 Cross references
273 Possible Orthologues:

Glutamate Receptor 4-Like

Ensembl ID : ENSLACG00000000691
Gene Symbol: LOC102365419
3 Cross references
321 Possible Orthologues:

Glutaminase

Ensembl ID : ENSLACG00000016381
Gene Symbol: GLS
3 Cross references
304 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).